Remedy and UC Berkeley launch wellness platform

Share this article:

Remedy Health Media is partnering with the University of California-Berkeley on BerkeleyWellness.com, which will deliver wellness information to consumers with the customary interactive spoonfuls of sugar—quizzes, slideshows, email alerts and social media feeds, along with roundtables and video chats featuring Berkeley experts.

Remedy and the Berkeley editorial board will collaborate on content, said Remedy. The site is expected to draw upwards of 1.25 million monthly unique visitors during its first quarter, the company said.

The site will be supported by advertising—inaugural advertisers include ProCure Proton Therapy Centers—pending approval of advertisers by a Berkeley review board, which the partners see as a differentiating point. It's in “very early beta” yet, said a Remedy spokesperson, but the aim is to establish a “device-agnostic platform” that engages proactive wellness info-seekers.

“We think wellness and prevention are going to become more important, and we're really excited about doing more on that side,” said CEO Michael Cunnion.

Remedy Health Media acquired HealthCentral in 2011 and last month launched Patient Health Services, a platform which allows docs to push condition-appropriate health and wellness information to patients.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...

Xtandi duo boosts rep force for pre-chemo push

Xtandi duo boosts rep force for pre-chemo push

With its label extended to the pre-chemo setting, the prostate cancer drug is poised to reach a new group of urologists, and could upend J&J's Zytiga.